Alopecia Areata – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Alopecia Areata Market Outlook

Thelansis’s “Alopecia Areata Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alopecia Areata treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alopecia Areata Overview

Alopecia areata is an autoimmune disorder that leads to temporary hair loss without scarring, with hair follicles remaining intact. Hair loss varies from distinct patches to widespread loss, affecting all hair-bearing areas, with scalp patchy alopecia being the most common. It impacts nearly 2% of the general population at some point. Most individuals with alopecia areata experience isolated circular hair loss patches on the scalp, eyebrows, eyelashes, or body, while some have extensive or total hair loss. Diagnosis is often based on hair loss patterns and history; occasionally, a biopsy may be required for confirmation. The typical age of diagnosis is 33, with males often diagnosed in childhood and females in adolescence—about 60% experience initial hair loss before age 20. Traditional treatments involve steroids administered via injection or topical application to affected areas. Steroids suppress the immune cells attacking hair follicles, promoting hair regrowth.

• The general population's prevalence is 0.1-0.2%, with a lifetime risk of 1.7%. Alopecia areata accounts for 0.7-3% of dermatologist consultations.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: